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between utilities and self-rated general health (GH, on a 5-point Likert scale), presence 
of several co-morbid conditions, and use of drugs. We assessed the responsiveness of 
CAT-5D-QOL by comparing changes in MAHU scores with changes in GH (anchor 
variable) between the two waves of the survey. RESULTS: There was a strong correla-
tion (Pearson r  0.77, n  520) between MAHU and WOMAC_HUI3 but the mean 
MAHU was signiﬁ cantly lower (0.79 vs. 0.86). No ceiling or ﬂ oor effect was observed
for either utility. Compared to WOMAC_HUI3, regression analysis demonstrated
generally stronger association for MAHU with the number of analgesic drugs taken 
and self-reported GH scores. MAHU also showed signiﬁ cant associations with the
presence of back pain, depression, ulcer, and cancer, whereas WOMAC_HUI3 corre-
lated only with back pain. In the analysis of responsiveness, differences in mean
MAHU scores were in the expected direction and signiﬁ cantly different for each level
of change in GH scores. CONCLUSIONS: MAHU and WOMAC_HUI3 were highly
correlated and neither measure had a ceiling or ﬂ oor effect. However, MAHU dem-
onstrated better discriminative ability with respect to several health-related variables.
MAHU was also sensitive to changes in overall health over time. These are all desirable 
properties for capturing the health impact of OA (and other conditions) and estimating 
cost-effectiveness of health interventions.
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OBJECTIVES: To validate the Oxford Knee Score (OKS) in outpatients with knee 
osteoarthritis (OA) in Shanghai. METHODS: Eligible patients were interviewed using 
a pretested questionnaire containing the OKS, the SF-6D, and the EQ-5D. Reliability
was assessed using Cronbach’s alpha, dimensionality using principal component factor
analysis and item-total correlations, convergent and discriminant construct validity 
using expected correlations between the OKS and the SF-6D and the EQ-5D. 
RESULTS: The Chinese OKS was well accepted by patients in a pilot testing. When 
administered to a convenient sample of 187 patients with knee OA (mean age 64 
years, 74% female, mean duration of OA 7.6 years), Cronbach’s alpha exceeded 0.8
and factor analysis yielded 2 factors with eigenvalue 1. Hypothesized item-total cor-
relations (¦Ñ q 0.4) were observed for all items. Convergent construct validity was 
supported by the presence of hypothesized moderate to strong correlations between
the OKS and SF-6D physical functioning, role limitation, social functioning, and pain,
EQ-5D mobility, self-care, usual activities, and pain/discomfort, and mobility VAS (¦Ñ 
 0.47 to 0.82). Discriminant construct validity was not satisfactory. The OKS corre-
lated weakly with SF-6D vitality (¦Ñ  0.35), but strongly with SF-6D mental health
and EQ-5D anxiety/depression (¦Ñ  0.51 and 0.41, respectively). CONCLUSIONS:
The OKS has demonstrated good psychometric properties and thus can be regarded
as a reliable and valid measurement in outpatients with OA.
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OBJECTIVES: Previous studies have suggested that adults with arthritis are less physi-
cally active than adults without arthritis. However, these studies were mostly based
on crude prevalence comparisons and general physical activity recommendations. Our 
objectives were: 1) to examine the physical activity proﬁ le of adults with arthritis; 2)
to compare physical activity in adults with arthritis with arthritis-speciﬁ c activity rec-
ommendations; and 3) to identify key determinants of participation in physical activ-
ity. METHODS: Using Statistics Canada’s 2005 Canadian Community Health Survey
(CCHS, n  132,221), we determined frequency of participation in different types of 
activity and calculated amount (minutes/day) of daily physical activity for adults with
self-reported, physician-diagnosed arthritis. Subjects met arthritis-speciﬁ c physical 
activity recommendations if they fulﬁ lled three criteria based on American College of 
Rheumatology guidelines: 1) total activity 15 minutes/day and participation in 2) 
aerobic exercise and 3) ﬂ exibility/strengthening exercise. Multiple logistic regression 
models were used to identify sociodemographic and health factors associated with
meeting physical activity recommendations. RESULTS: There were 23,503 subjects 
with reported physician-diagnosed arthritis (prevalence, 15.1%) in the CCHS. Of 
these, 61% performed 15 minutes/day of activity; the most frequently reported 
aerobic and ﬂ exibility/strengthening exercises were walking (65.7%) and home exer-
cise (30.5%), respectively. Overall, 26% of subjects met arthritis-speciﬁ c physical
activity recommendations. Factors that were associated with meeting recommenda-
tions included being female (adjusted OR 1.16 [1.08–1.23]) and having post-second-
ary education (1.93 [1.78–2.09]). Negatively associated factors included smoking 
(0.62 [0.57–0.68]), and overweight (0.80 [0.74–0.86]) and obese status (0.58 [0.54–
0.63]). CONCLUSIONS: We found that 26% of adults with arthritis met speciﬁ c
activity recommendations. Examination of speciﬁ c activities identiﬁ ed walking as an
important contributor to aerobic and total activity in people with arthritis. In addition, 
evaluation of correlates of physical activity identiﬁ ed males, overweight or obese 
individuals and those with lower education levels as target groups for potential inter-
vention strategies.
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OBJECTIVES: To evaluate the impact of golimumab (GLM) on productivity in anky-
losing spondylitis (AS) patients. METHODS: GLM was studied in a multicenter, ran-
domized, placebo (PBO)-controlled study (GO-RAISE) in which 356 patients were 
randomized (1.8:1.8:1 ratio) to receive subcutaneous GLM 50 mg, 100 mg, or PBO
q4 wks. Patients with Ankylosing Spondylitis (AS) (BASDAI and back pain score each 
q4) were eligible. Productivity was measured on a VAS scale (0–10 cm). Change in
productivity from baseline to wk16 and wk24 was compared between groups. At 
wk16, patients who received PBO or GLM 50 mg and had 20% improvement in 
total back pain and morning stiffness entered early escape in a double-blind fashion.
All other patients remained on their previous medication until wk24. The last observa-
tion for patients who entered early escape prior to change in treatment was carried 
forward in the wk24 analyses. Observed values at wk24 were used for GLM 100 mg 
patients. An ANOVA on van der Waerden normal scores was performed for between-
group differences. RESULTS: Patients in the GLM 50 mg, 100 mg, and PBO groups 
had similar mean o SD baseline scores of 6.6 o 2.5, 6.8 o 2.3, and 6.3 o 2.5, respec-
tively. Mean improvement in self-reported productivity was signiﬁ cantly greater with 
the GLM 50 mg group than the PBO group at wk16 (2.8 o 3.0 vs. 0.4 o 2.7; p 
0.001) and wk24 (2.7 o 3.1 vs. 0.5 o 3.0; p  0.001). Signiﬁ cantly greater improve-
ment was observed with the GLM 100 mg group than the PBO group at wk16 (2.9 
o 2.9 vs 0.4 o 2.7; p  0.001) and wk24 (2.9 o 3.0 vs. 0.5 o 3.0; p  0.001). 
Change from baseline in productivity was similar in both GLM dose groups at wk16 
and wk24. CONCLUSIONS: AS patients treated with GLM 50 mg and 100 mg had 
signiﬁ cant improvement in self-reported productivity, with improvement at wk16 
maintained through wk24.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on self-reported productiv-
ity in rheumatoid arthritis (RA) patients. METHODS: The effect of GLM on self-
reported productivity was evaluated in three multicenter, randomized, double-blind, 
placebo (PBO)-controlled studies in RA patients. The trials evaluated different 
patient populations and included patients naïve to MTX (GO-BEFORE), patients with
active RA despite MTX (GO-FORWARD), and patients previously treated with anti-
TNF-alpha agent(s) (GO-AFTER). GLM subcutaneous injections of 50 mg or 100 mg 
were administered q4ks. At wks0 and 24, patients rated their productivity on a VAS
scale (0–10 cm) at work, school or at home after 4wks. A negative mean change from 
baseline is an improvement in self-reported productivity. An ANOVA on van der
Waerden normal scores was performed for between-group comparisons. RESULTS:
Mean baseline scores for self-reported productivity were comparable between groups
(ranges were 6.3–6.4[GO-BEFORE]; 5.4–5.7[GO-FORWARD], 6.2–6.7[GO-AFTER]). 
In GO-FORWARD, the mean(SD) improvements in self-reported productivity were 
signiﬁ cantly greater in the GLM 50 and 100 mg  MTX groups compared with PBO 
 MTX at wk24 (1.97 o 3.12, 2.00 o 2.53, and 0.45 o 2.98, respectively, p 
0.001). In GO-AFTER, the mean(SD) improvements in self-reported productivity 
were signiﬁ cantly greater in the GLM 50 and 100 mg groups compared with PBO at 
wk24 (1.77 o 2.90, 2.10 o 2.92, and 0.52 o 2.79, respectively, p  0.001). In 
GO-BEFORE, numerical improvements in self-reported productivity were observed in
the GLM 50 and 100 mg MTX groups (2.48 o 2.94 and 2.90 o 2.80, respectively); 
these improvements were not signiﬁ cantly different from PBO  MTX (2.27 o 3.02). 
CONCLUSIONS: In two studies, GLM resulted in signiﬁ cant improvements in self-
reported productivity. In the third trial, GLM resulted in trends towards improvement
in self-reported productivity compared with PBOMTX.
